Cases & Deals

  • Home
  • Practices
  • Allorion Therapeutics announces global license deal of ARTS-021, a clinical stage CDK2 inhibitor, with Avenzo Therapeutics, Inc.

Share

Allorion Therapeutics announces global license deal of ARTS-021, a clinical stage CDK2 inhibitor, with Avenzo Therapeutics, Inc.

January 2024

Client(s) Allorion Therapeutics Inc

Jones Day represents Allorion Therapeutics in patent matters and assisted in defending the intellectual property diligence in the company's global license deal of ARTS-021, a clinical stage CDK2 inhibitor, with Avenzo Therapeutics, Inc.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.